Evidence map›Paper›PMID 42567684›Full record

ArticleLife science alliance2026

Clonal

Kunal M Shah, Paul T Kennedy, James Rm Black, Piotr Pawlik, Kevin Litchfield, Krupa Thakkar, Maria F Contreras-Gerenas, Kirsten Brooksbank, Oliver Yuan, Paul Grevitt and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life science alliance, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kunal M ShahThe Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK k.shah@qmul.ac.uk.ORCID https://orcid.org/0000-0002-4508-9606
Paul T KennedyDepartment of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
James Rm BlackUCL Cancer Institute, London, UK.
Piotr PawlikUCL Cancer Institute, London, UK.ORCID https://orcid.org/0009-0008-7075-615X
Kevin LitchfieldUCL Cancer Institute, London, UK.
Krupa ThakkarUCL Cancer Institute, London, UK.
Maria F Contreras-GerenasThe Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK.
Kirsten BrooksbankThe Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK.
Oliver YuanThe Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK.
Paul GrevittThe Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK.ORCID https://orcid.org/0000-0001-8224-1315
Sarah CharrotThe Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK.
Jeff DaviesThe Centre for Haemato-Oncology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK.
Lekh N DahalDepartment of Pharmacology and Therapeutics, University of Liverpool, Liverpool, UK.
Dimitris LagosHull York Medical School, University of York, Heslington, York, UK.ORCID https://orcid.org/0000-0003-0637-281X
Nicholas McGranahanUCL Cancer Institute, London, UK.
Tyson V SharpThe Centre for Cancer Cell and Molecular Biology, Barts Cancer Institute, Queen Mary University of London, John Vane Science Centre, London, UK t.sharp@qmul.ac.uk.ORCID https://orcid.org/0000-0003-1861-7984

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

LIMD1, a tumour suppressor located at chromosome 3p21.3, is frequently lost in non-small-cell lung cancer, yet its role in tumour-immune interactions remains unclear. Here, we show LIMD1 loss increases PD-L1 protein abundance across multiple lung cancer models and primary airway epithelial cells. Mechanistically, LIMD1 restrains PD-L1 through post-transcriptional and post-translational mechanisms. LIMD1 loss can relieve microRNA-mediated repression of the

Indexed as

B7-H1 AntigenImmune EvasionLIM Domain ProteinsLung NeoplasmsAnimalsCarcinoma, Non-Small-Cell LungCD8-Positive T-LymphocytesCell Line, TumorGene Expression Regulation, NeoplasticHumansMicroRNAsUbiquitinationB7-H1 AntigenCD274 protein, humanLIM Domain ProteinsMicroRNAs

Identifiers

PMID42567684
PMCPMC13451150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.